Aldali Jehad A, Aldali Hamzah J, Aljohani Razan, Algahtani Mohammad, Meo Sultan Ayoub, Alharbi Saad, Al-Afghani Hani, Aldabaseh Linda Nazmi, Al Rubai Elham Hamed, Fallata Abdulaziz, Zahrani Saleh Abdullah, Al Zahrani Mohanad Atiah
Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia.
Cellular and Molecular Medicine, College of Biomedical Science, University of Bristol, Bristol City BS8 1QU, UK.
Microorganisms. 2023 Jul 28;11(8):1921. doi: 10.3390/microorganisms11081921.
The clinical severity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection may rise because of acquiring a co-infection during the hospital stay of the patients. The rate of hospital co-infection alongside COVID-19 infection remains low. However, the mortality rates and intensive care unit (ICU) admission remains ambiguous. The present study investigates the implications of COVID-19 hospitalised infected patients with co-infection and the clinical outcomes. In this study, 142 patients were included. The eligible patients who tested positive for COVID-19 infection were hospitalised for more than two days. Each patient's characteristics and laboratory results were collected, such as who was admitted to the intensive care unit and who was discharged or expired. The results revealed that out of the 142 hospitalised patients, 25 (17.6%) were co-infection positive, and 12 identified types of co-infection: two Gram-positive bacterial infections, one fungal infection and nine Gram-negative bacterial infections. In addition, 33 (23.2%) were ICU admitted, 21 were co-infection negative and 12 were co-infection positive. Among the 12 ICU admitted with co-infection, 33.4% were discharged. The death rate and ICU admission had a -value < 0.05, indicating statistical significance for co-infected patients compared to non-co-infected patients. It was concluded that co-infection remains very low within hospitalised COVID-19-infected patients but can have severe outcomes with increased ICU admission and increased mortality rates. Thus, implementing infection preventive measures to minimize the spread of hospital-acquired infections among COVID-19 hospitalised patients.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的临床严重程度可能因患者住院期间合并感染而升高。与2019冠状病毒病（COVID-19）感染同时发生的医院内合并感染率仍然较低。然而，死亡率和重症监护病房（ICU）收治率仍不明确。本研究调查了合并感染的COVID-19住院感染患者的情况及临床结局。本研究纳入了142例患者。COVID-19感染检测呈阳性且符合条件的患者住院超过两天。收集了每位患者的特征和实验室检查结果，如谁被收治入重症监护病房、谁出院或死亡。结果显示，在142例住院患者中，25例（17.6%）合并感染呈阳性，共识别出12种合并感染类型：2例革兰氏阳性菌感染、1例真菌感染和9例革兰氏阴性菌感染。此外，33例（23.2%）被收治入ICU，其中21例合并感染呈阴性，12例合并感染呈阳性。在12例合并感染且被收治入ICU的患者中，33.4%出院。死亡率和ICU收治率的P值<0.05，表明合并感染患者与未合并感染患者相比具有统计学意义。研究得出结论，COVID-19住院感染患者中合并感染率仍然很低，但可能导致严重后果，表现为ICU收治率增加和死亡率上升。因此，应实施感染预防措施，以尽量减少COVID-19住院患者中医院获得性感染的传播。
